Succaria, Farah Kvistborg, Pia Stein, Julie E Engle, Elizabeth L McMiller, Tracee L Rooper, Lisa M Thompson, Elizabeth Berger, Alan E van den Brekel, Michiel Zuur, Charlotte L
...
Published in
Cancer immunology, immunotherapy : CII
Approximately 15% of advanced head and neck squamous cell carcinomas (HNSCC) respond to anti-PD-(L)1 monotherapies. Tumor PD-L1 expression and human papillomavirus (HPV) status have been proposed as biomarkers to identify patients likely to benefit from these treatments. We aimed to understand the potential immune effects of HPV in HNSCC and to cha...
Woo, Ji Won Chung, Yul Ri Kim, Milim Choi, Hye Yeon Ahn, Soomin Park, So Yeon
Published in
Cancer immunology, immunotherapy : CII
Myeloid-derived suppressor cells (MDSCs) play an important role in tumor progression through both immunologic and non-immunologic mechanisms. This study was conducted to evaluate the expression of S100A8, a well-known MDSC marker, and the significance of its expression in pre-invasive and invasive breast cancers. S100A8 expression in tumor cells (T...
McGehee, Elizabeth Patel, Hetalkumari Pearson, Caroline Clements, Keri Jaso, Jesse Manuel Chen, Weina Callan, Alexandra Desai, Neil Ramakrishnan Geethakumari, Praveen
Published in
Journal of Medical Case Reports
BackgroundExtranodal natural killer/T-cell lymphoma is a rare, aggressive non-Hodgkin lymphoma that is treated upfront mostly with L-asparaginase containing regimens. Relapsed extranodal natural killer/T-cell lymphoma is associated with a poor prognosis, and there is no established standard of care.Case presentationWe report the case of a 72 year-o...
Leite, Kátia Ramos Moreira Barrios, Carlos Henrique Buzaid, Antônio Carlos Gagliato, Débora Gobbi, Helenice Soares, Fernando
Published in
Surgical and Experimental Pathology
BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less.Main textNew targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A pane...
Zhang, Lei Liu, Huanhuan Tian, Ye Wang, Huina Yang, Xueying
Published in
BMC Pulmonary Medicine
BackgroundThe identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor. It is not clear whether the NTRK breakpoint location is different for response to targeted therapy and NTRK fusions affects the efficacy of immunotherapy.Case presentationHere we reported a 60...
Xu, Guili Zhang, Peng Liang, Hansi Xu, Yunhua Shen, Jian Wang, Wansheng Li, Mingming Huang, Jintao Ni, Caifang Zhang, Xueguang
...
Published in
Cancer Cell International
BackgroundEpithelial-mesenchymal transition (EMT) has been associated with wound healing, tumorigenesis, and metastasis. Circular RNAs (circRNAs) are functional non-coding RNAs involved in multiple human cancers. However, whether and how circRNAs contribute to the EMT in hepatocellular carcinomas (HCC) remains to be deciphered. In this study, we in...
Özdoğan, Mustafa Papadopoulou, Eirini Tsoulos, Nikolaos Tsantikidi, Aikaterini Mariatou, Vasiliki-Metaxa Tsaousis, Georgios Kapeni, Evgenia Bourkoula, Evgenia Fotiou, Dimitrios Kapetsis, Georgios
...
Published in
BMC Medical Genomics
BackgroundTumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers of response to targeted treatment. In parallel with targeted therapies, immunotherapies are also evolving, revolutionizing cancer therapy, with Programmed Death-l...
Merino, María Lozano, Teresa Casares, Noelia Lana, Hugo Troconiz, Iñaki F. ten Hagen, Timo L. M. Kochan, Grazyna Berraondo, Pedro Zalba, Sara Garrido, María J.
...
Published in
Journal of Nanobiotechnology
BackgroundThe immunomodulation of the antitumor response driven by immunocheckpoint inhibitors (ICIs) such as PD-L1 (Programmed Death Ligand-1) monoclonal antibody (α-PD-L1) have shown relevant clinical outcomes in a subset of patients. This fact has led to the search for rational combinations with other therapeutic agents such as Doxorubicin (Dox)...
Hua, S Gu, M Wang, Y Ban, D Ji, H
Published in
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Colorectal cancer (CRC) represents an important neoplasm with high mortality. Although PD-L1/PD-1 system-based immunotherapy has benefits for a certain type of CRC, many efforts should be made to enhance the responses to anti-PD-1/PD-L1 drugs. DNA methylation has been critically implicated in the regulation of tumor immunity. Here, we examined the ...
Kim, Sang Kyum Kim, Jee Hung Kim, Seung Hyun Lee, Young Han Han, Jung Woo Baek, Wooyeol Woo, Ha Young Jeon, Min Kyung Kim, Hyo Song
Published in
BMC Cancer
BackgroundPazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predictive impact of PD-L1, we investigated the clinical relevanc...
